Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625 1628 1672
This examiner grants 73% of resolved cases
Yevgeny Valenrod serves in Tech Center 1600 and Art Unit 1621. His record includes 1025 resolved cases with an allowance rate pct of 72.6%. This 72.6% rate suggests a favorable environment for applicants. The median days to allowance is 933, which indicates the typical timeframe for reaching a positive outcome. Practitioners should factor this 933 days duration into their expectations for Art Unit 1621. This 933 days timeline is a key metric for Tech Center 1600.
The data also shows an interview lift pct of 25.1%. This 25.1% figure indicates that interviews provide a significant benefit, increasing the probability of success beyond the 72.6% base rate. With 1025 resolved cases, the examiner's tendencies are well-documented. The 25.1% lift suggests that direct communication is a highly effective tool for resolving issues. Applicants can use the 72.6% allowance rate and the 25.1% lift to optimize their prosecution strategy. The 933 days median pendency remains a stable benchmark for planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19567925 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Non-Final OA | Amazentis SA |
| 19311619 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Non-Final OA | Amazentis SA |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Non-Final OA | Amazentis SA |
| 18205305 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Non-Final OA | Amazentis SA |
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Final Rejection | Deciphera Pharmaceuticals, LLC |
| 18290630 | AUTOMATED SYNTHESIS OF POLYMERIC DRUGS | Non-Final OA | SONY GROUP CORPORATION |
| 18848613 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | Non-Final OA | Ohio State Innovation Foundation |
| 18703008 | ARYLIMIDAMIDES FOR USE IN TREATMENT OF CANCERS | Non-Final OA | Ohio State Innovation Foundation |
| 18613203 | Small Molecule Targeting of BRD4 for Treatment of COVID-19 | Final Rejection | Board of Regents, The University of Texas System |
| 18687599 | Dosing Regimen for a TEAD inhibitor | Non-Final OA | Novartis AG |
| 18565626 | METHODS OF TREATMENT | Final Rejection | Arena Pharmaceuticals, Inc. |
| 18031772 | USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS | Non-Final OA | PACYLEX PHARMACEUTICALS INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy